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Abstract: Human Campylobacter jejuni infections inducing campylobacteriosis including
post-infectious sequelae such as Guillain-Barré syndrome and reactive arthritis are rising worldwide
and progress into a global burden of high socioeconomic impact. Intestinal immunopathology
underlying campylobacteriosis is a classical response of the innate immune system characterized by
the accumulation of neutrophils and macrophages which cause tissue destruction, barrier defects and
malabsorption leading to bloody diarrhea. Clinical studies revealed that enteritis and post-infectious
morbidities of human C. jejuni infections are strongly dependent on the structure of pathogenic
lipooligosaccharides (LOS) triggering the innate immune system via Toll-like-receptor (TLR)-4
signaling. Compared to humans, mice display an approximately 10,000 times weaker TLR-4 response
and a pronounced colonization resistance (CR) against C. jejuni maintained by the murine gut
microbiota. In consequence, investigations of campylobacteriosis have been hampered by the lack
of experimental animal models. We here summarize recent progress made in the development of
murine C. jejuni infection models that are based on the abolishment of CR by modulating the murine
gut microbiota and by sensitization of mice to LOS. These advances support the major role of LOS
driven innate immunity in pathogenesis of campylobacteriosis including post-infectious autoimmune
diseases and promote the preclinical evaluation of novel pharmaceutical strategies for prophylaxis
and treatment.
Keywords: Campylobacter jejuni; campylobacteriosis; lipooligosaccharide (LOS); pathogenicity;
intestinal pathogenesis; toll-like receptor
1. Introduction
The foodborne bacterial pathogen Campylobacter jejuni is recognized as one of the leading causes
of infectious bacterial enteric infections worldwide [1–7]. Since 2005, campylobacteriosis has been
the most frequently reported bacterial zoonosis in the European Union, exceeding salmonellosis
by a continuously increasing number of cases [8]. Among more than 30 Campylobacter species and
subspecies, C. jejuni and C. coli are the most common subpopulations causing human infections [9].
The Gram-negative, slender, spirally-curved, flagellated C. jejuni bacteria are highly motile and
grow under microaerophilic conditions in a temperature range between 37 and 42 ◦C [10–12]. C. jejuni
is present in surface waters and forms part of the natural intestinal microbiota of a wide range of wild
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animals as well as of agriculturally essential mammals and birds, especially poultry [9,11]. Recently, a
study on pathogen isolates from humans and chicken confirmed the transmission of C. jejuni between
the two species, underlining the significance of poultry as a source of human C. jejuni infections [13].
In fact, in the majority of disease cases, humans become infected via the consumption of undercooked
meat of contaminated livestock animals or by ingestion of raw milk and surface water containing C.
jejuni [14,15].
Depending on the Campylobacter strain and the host immune status, patients might present with
a highly acute and severe symptom complex varying from watery diarrhea without fever and/or
abdominal cramps to severe campylobacteriosis characterized by purulent bloody inflammatory
diarrhea and systemic inflammatory responses including fever [9,16–18]. The infection is usually
self-limiting and lasts for several days to two weeks [19,20]. However, in the minority of cases,
post-infectious sequelae such as Guillain-Barré syndrome (GBS), Miller Fisher syndrome (MFS), reactive
arthritis (RA) or chronic intestinal inflammatory morbidities including inflammatory bowel disease
(IBD), irritable bowel syndrome (IBS) or celiac disease might develop [4,9,18,21–23]. A clinical study
revealed that both the severity of campylobacteriosis and the development of post-infectious sequelae
are significantly associated with sialylated lipooligosaccharide (LOS) structures localized in the outer
cell membrane of C. jejuni [22]. Although the O-antigen characteristic of bacterial lipopolysaccharide
(LPS) is missing in C. jejuni LOS [24,25], the structural variability of LOS provides the basis for
the highly variable disease manifestation in humans. This finding was of great importance for the
molecular understanding of the substantial role of C. jejuni LOS in intestinal immunopathogenesis of
campylobacteriosis, which will be discussed further.
2. Basic Concept and Aim of This Review Article
Similar to the vast majority of bacterial enteric pathogens causing inflammatory diseases in the
gastrointestinal tract, C. jejuni enters the gut via ingestion of food contaminated with a low number of
live bacteria [26]. After replication at body temperature and establishment of a primary population,
the highly motile C. jejuni pass the barriers of the viscous mucus layer (Figure 1) and the epithelial cell
lining with the help of polar flagella, adhesins, and invasins including potent proteases such as HtrA
further supporting transcellular migration of the bacteria [27–30]. Most recently, the type VI secretion
system (T6SS) of C. jejuni was discovered as a factor which might be involved in virulence. This system
enables the contact-dependent secretion of effector proteins into host cells and even other bacteria [31].
However, the role of T6SS in campylobacteriosis is still unclear. Whereas results from several studies
suggested that T6SS is associated with more severe disease [31,32], a recent clinical study demonstrated
that the T6SS does not contribute to the severity of campylobacteriosis, as shown by analysis of human
patients infected with T6SS negative and positive C. jejuni strains [33]. In contrast to the following
inflammatory response, these “barrier breaking bacterial factors” are very well investigated at the
molecular level and it has been established for decades that motility, adhesion and invasion are essential
for C. jejuni pathogenicity and virulence (Figure 1). However, the analysis of biopsies taken from
human patients revealed that C. jejuni reaching the lamina propria and the sub-epithelial tissues initiate
a pronounced innate immune response, characterized by massive conglomerates of macrophages and
neutrophilic granulocytes leading to acute inflammation [4,34–37]. The production of toxic oxygen
radicals and cytokines over the course of this innate immune response further leads to apoptosis, tissue
destruction and ulcerations, which finally pave the way for sodium malabsorption, followed by water
efflux and bloody diarrhea [37] (Figure 1).
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of C. jejuni (Figure 2) has been identified as an essential virulence factor playing pivotal roles in host 
cell adhesion and invasion in vitro, as well as in evasion of host defense reactions [11,24,39–41]. The 
important role of LOS was most recently confirmed in a clinical study investigating the intestinal 
immunopathology in C. jejuni infected humans, which revealed that bacterial LOS is the master 
regulator of the innate immune responses in the onset and progress of human campylobacteriosis 
[37]. Structurally, LOS participates in the management of bacterial outer membrane stability and 
protects the C. jejuni cells from environmental stress conditions including host immune responses 
[24,42]. However, further analysis of LOS functions in campylobacteriosis has been hampered by the 
lack of suitable murine infection models.   
In contrast to humans, conventional mice are well protected from C. jejuni infection and do not 
develop clinical signs after experimental intestinal colonization [43]. This can be attributed to the fact 
that mice are approximately 10,000-fold less responsive to Toll-like receptor (TLR)-4 ligands, mainly 
LOS and LPS [44] (Figure 3). Furthermore, the gastrointestinal microbiota of conventional mice 
mediates a strong colonization resistance (CR) to C. jejuni [45–47]. In line with other investigators, we 
have recently shown that conventional mice bred in our specific pathogen-free (SPF) facilities are 
protected from stable gastrointestinal C. jejuni colonization even upon peroral infection with high 
doses. Upon modifying the murine gut microbiota (i.e., its virtual depletion) following broad-
spectrum antibiotic treatment, and also upon re-association with human as opposed to murine gut 
microbiota by fecal microbiota transplantation, these mice can be effectively colonized by the 
Figure 1. Campylobacter jejuni induced immunopathological responses within the intestinal tract.
The highly motile C. jejuni circumvent the mucus layer, cross the intestinal epithelial layer and interact
with mucosal and lamina propria cells, resulting in the recruitment of dendritic cells, macrophages, and
neutrophils. The interaction of these innate immune cells with the lipooligosaccharide (LOS) of C. jejuni
mounts a massive pro-inflammatory cytokine response via TLR-4 signaling, inducing apoptosis and
ulcerations in the epithelial layer, progressing into barrier defects, malabsorption and bloody diarrhea.
Given the absence of potent C. jejuni toxins common to all infecting bacterial strains, the full-blown
symptom complex of campylobacteriosis is caused by the innate immune responses induced by
sialylated LOS variants A, B, and C, as shown in a clinical study focusing on factors mediating
human campylobacteriosis [23]. In this aspect, campylobacteriosis mirrors key features of the
immunopathogenesis during meningitis and urethritis caused by pathogenic Neisseria meningitidis
and N. gonorrhoeae, respectively, both of which express LOS as a m jor pathogenicity factor on their
bacterial surfac [38] (Figure 1).
In addition to its functions in the initiation and propag tion of in stinal inflammat on the LOS
of C. jejuni (Figure 2) ha been identified as an ential virulence factor playing pivotal roles in
host cell adhesion and invasion in vitro, as well as in evasion of host defense reactions [11,24,39–41].
The important role of LOS was most recently confirmed in a clinical study investigating the intestinal
immunopathology in C. jejuni infected humans, which revealed that bacterial LOS is the master
regulator of the innate immune responses in the onset and progress of human campylobacteriosis [37].
Structurally, LOS participates in the management of bacterial outer membrane stability and protects the
C. jejuni cells from environmental stress conditions including host immune responses [24,42]. However,
further analysis of LOS functions in campylobacteriosis has been hampered by the lack of suitable
murine infection models.
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Figure 2. The basal structure of C. jejuni LOS. The LOS of C. jejuni consists of Lipid A, phostoethanolamine
(PEA), 3-Deoxy-d-manno-oct-2-ulosonic acid or keto-deoxyoctulosonate (Kdo), Heptose (Hep), glucose
(Glu), galactose (Gal), N-acetylgalactosamine (GalNAc), and N-acetylneuraminic acid (Neu5Ac) and in
sialylated form mimics a range of gangliosides (e.g., GM1). The characteristic O-antigen of LPS from
Gram-negative bacteria is missing.
In contrast to humans, conventional mice are well protected from C. jejuni infection and do not
develop clinical signs after experimental intestinal colonization [43]. This can be attributed to the
fact that mice are approximately 10,000-fold less responsive to Toll-like receptor (TLR)-4 ligands,
mainly LOS and LPS [44] (Figure 3). Furthermore, the gastrointestinal microbiota of conventional mice
mediates a strong colonization resistance (CR) to C. jejuni [45–47]. In line with other investigators,
we have recently shown that conventional mice bred in our specific pathogen-free (SPF) facilities are
protected from stable gastrointestinal C. jejuni colonization even upon peroral infection with high
doses. Upon modifying the murine gut microbiota (i.e., its virtual depletion) following broad-spectrum
antibiotic treatment, and also upon re-association with human as opposed to murine gut microbiota
by fecal microbiota transplantation, these mice can be effectively colonized by the pathogen upon
peroral challenge and display typical histopathologic pro-inflammatory features of campylobacteriosis
in their intestines [46–49], whereas the classic symptoms such as abdominal cramps, watery, or
bloody diarrhea seen in infected humans were missing in conventional wildtype mice without genetic
manipulations [46] (Figure 4).
In order to generate murine infection models mirroring clinical features of severe
campylobacteriosis, researchers including our group—independently from each other—modified the
microbiota in order to overcome CR, as well as LOS sensitivity via different genetic manipulations or
by zinc depletion, which all in turn affect LOS/TLR-4 dependent signaling pathways [50–54] (Figure 4).
Although experimental advances have been achieved for a better understanding of human
campylobacteriosis, it is not yet fully understood how the host response itself is established at the
cellular and molecular levels. However, several studies have suggested that the structure of C. jejuni
LOS is indeed responsible for the outcome of infection and for the development of post-infectious
sequelae [22,55]. In this review, we aim to summarize the development of novel clinical murine models
of C. jejuni infection and their successful application in the study of major roles of C. jejuni LOS in the
immunopathogenesis of campylobacteriosis (summarized in Tables 1 and 2).
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Figure 3. C. jejuni LOS and TLR-4 Signaling. The activation of TLR-4 leads to the synthesis of
infla atory mediators via two different pathways; TRIF-TRAM pathway, which induces the secretion
of tumor necrosis factor alpha and TIRAP-MyD88, which is responsible for the LOS response and
NF-κB activation.
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Figure 4. Modulation of Ca pylobacter jejuni infection by host and dietary factors. Both host and dietary
factors interact with the immune responses upon C. jejuni infection at different levels thereby affecting
the outcome of disease.
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of C. jejuni LOS Sensitized
Macroscopic
Signs of Disease Inflammatory Responses Reference
C57BL/6 SPF No/No Low No No Elevated T-helper-1 cell responses in intestinalcompartments [56]
C57BL/6 SPF No/No No No No
Intestinal epithelial cell apoptosis and
proliferation/regeneration, moderate cellular
and molecular inflammatory responses
[46]
C57BL/6 No-SA Yes/No High No No
Intestinal epithelial cell apoptosis and
proliferation/regeneration, pronounced
cellular and molecular inflammatory responses
[46]
C57BL/6 SA plus rHF Yes/No Moderate No No
Intestinal epithelial cell apoptosis and
proliferation/regeneration, pronounced
cellular and molecular inflammatory responses
[46]
BALB/c Neonatal SPF No/No Moderate Yes Wasting, bloodydiarrhea ND [57]




Intestinal epithelial cell apoptosis and
proliferation/regeneration, elevated




Zinc deficient Depleted Yes/Zinc depleted High Yes
Wasting, bloody
diarrhea
Intestinal edema, pronounced neutrophilic
infiltration, crypt hyperplasia, intestinal and
systemic inflammatory mediator responses
[53]
ND, not determined; SA, secondary abiotic; rHF, recolonized with human microbiota; SPF, specific pathogen-free murine microbiota.
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Signs of Disease Inflammatory Responses Reference
BALB/c Athymic (nu/nu)Euthymic (+/nu) No, GF No Yes Transient diarrhea
Cecal shrinkage, accumulation of eosinophils in the
lower intestinal mucosa and lamina propria,
translocation of viable C. jejuni to MLN, spleen, liver
and kidneys
[59,60]
C57BL/6 IL-10−/− SPF No Yes Wasting, bloodydiarrhea
Severe typhlocolitis and gross pathological changes
in the gastrointestinal tract, increased immune cell
responses and production of
pro-inflammatory mediators
[56]
129/SvEv IL-10−/− No, GF No Yes Wasting, bloodydiarrhea
Intestinal crypt abscesses and epithelial ulcerations.
Increased mononuclear cells, neutrophils, and
elevated pro-inflammatory mediators
[61]
129/SvEv C57BL/6 IL-10−/− No, GF No Yes Wasting, bloodydiarrhea
Pronounced neutrophilic infiltration of the
intestines; increased NF-κB activity and Il1β, Cxcl2,
Il17a expression
[62,63]
C57BL/10 IL-10−/− No, SA Yes Yes Wasting, bloodydiarrhea
Increases in apoptotic intestinal epithelial cells.
Pronounced innate and adaptive immune cell
responses, elevated intestinal pro-inflammatory
mediators. Translocation of viable C. jejuni to MLN,
extra-intestinal including systemic inflammation
[50,64]
C57BL/6 SIGIRR−/− Modified Yes Yes ND
Increases in intestinal granulocytes, goblet cell
depletion, edema, elevated pro-inflammatory
mediators, translocation of C. jejuni to
subepithelial tissues
[54]
ND, not determined; SA, secondary abiotic; SPF, specific-pathogen-free murine microbiota; GF, germfree; MLN, mesenteric lymph nodes.
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3. Human Campylobacteriosis
Human C. jejuni infections are mostly self-limiting [9] and resolve within approximately 7 to 14
days [19,35], whereas some patients develop a more chronic form of Campylobacter colitis, however [65].
Interestingly, recent studies revealed that C. jejuni infection might increase the risk for development
and relapses of IBD, IBS or celiac disease [66].
The development of C. jejuni-induced human enterocolitis occurs at different stages characterized
by distinct immune responses upon infection [35]. In the early stage (i.e., the first week, during acute
enterocolitis), epithelial and pathological changes predominantly in distal parts of the large intestinal
tract are caused by a massive accumulation of macrophages and neutrophilic granulocytes in crypts
and in the lamina propria (Figure 1). In the later stage (i.e., the second week), the symptoms of
inflammation become less pronounced and the regeneration of the affected epithelia starts. After two
weeks, in the residual stage, the inflammatory changes are almost completely resolved. Interestingly,
regardless of the infection stage, C. jejuni bacteria have been detected immunohistochemically in
colonic biopsies derived from patients with C. jejuni positive stool cultures [35].
Despite the described clinical picture, it is still neither completely clear at the cellular nor
the molecular level how C. jejuni induces the macrophages and neutrophilic granulocytes driven
inflammatory responses in humans. A multitude of in vitro studies confirmed that, in addition to
the above-mentioned pathogenicity factors, various virulence factors including invasive properties,
oxidative stress defense, cytolethal-distending toxin production, and iron acquisition, are required for
full C. jejuni pathogenicity in cell cultures [7,67–69].
Most importantly, the bacterial surface LOS has been identified as an essential virulence factor of C.
jejuni playing key roles in host cell adhesion and invasion as well as in the attraction and accumulation
of macrophages and granulocytes to the sites of intestinal bacterial invasion [11,24,39–41]. In vitro
studies revealed that sialylation of C. jejuni LOS enhances the invasive potential of the pathogen and
may further contribute to the evasion of attacking antibodies [39,70,71]. Since the distinct C. jejuni
LOS structure (Figure 2) is associated with campylobacteriosis severity and post-infectious sequelae
such as GBS, a better understanding of the molecular mechanisms underlying both intestinal and
extra-intestinal disease manifestations is of basic importance for the development of novel strategies in
order to prevent or treat human C. jejuni-induced disease.
4. C. jejuni Lipooligosaccharide and Post-Infectious Sequelae in Human Campylobacteriosis
The results from several clinical studies demonstrate that the hyper-activation of the innate immune
system by sialylated C. jejuni LOS triggers the development of severe forms of campylobacteriosis and
increases the risk for development of post-infectious sequelae such as GBS [22,72] (Figure 2) The majority
of C. jejuni strains produce LOS mimicking distinct surface structures of human gangliosides [73].
Antibodies directed against LOS hence might react with human peripheral nerves following C. jejuni
infection [74]. Interestingly, GBS itself is triggered by these autoantibodies produced in response to LOS
of C. jejuni strains [75]. Specifically, C. jejuni strains of the classes A, B and C, known as the ABC group,
received lots of attention due to their possession of coding genes for the sialic acid-processing enzymes
and glycosyltransferases, which are required for the synthesis of ganglioside-like glycans [45,71,76].
In one study, the LOS outer-cores of 26 C. jejuni strains (22 associated with GBS, four associated with
MFS) were analyzed via mass spectrometry and revealed that almost all strains expressed LOS with
structural similarities to gangliosides in nerve fibers [73]. Genes for production of sialylated LOS
classes have been found predominantly in GBS-associated C. jejuni strains [77]. Furthermore, it has
been suggested that C. jejuni strains with sialylated LOS have a higher invasive potential in cell cultures,
and that inactivation of LOS sialyltransferase results in the loss of such invasiveness [78]. However,
a recent study reported that the sialylation of LOS is not necessary for the C. jejuni invasiveness,
given that only 23% of isolates from patients with C. jejuni bacteremia belonged to LOS locus classes
indicative of a potential to sialylate the LOS [55].
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Together, these findings support the view that C. jejuni LOS constitutes a major pro-inflammatory
trigger for severe forms of human campylobacteriosis and plays an important role in the
immunopathogenesis of post-infectious sequelae such as GBS and MFS [45].
5. Structural Aspects of C. jejuni Lipooligosaccharide
The C. jejuni LOS consists of the hydrophobic lipid A anchor and an oligosaccharide with a
conserved inner and a variable outer core (Figure 2) [39,79]. The LOS biosynthesis genes in C. jejuni are
localized at a hypervariable locus with 19 identified classes [80], which may explain the variation in C.
jejuni-associated pathologies [81,82].
Molecular analyses demonstrated that the C. jejuni GB11 strain (isolated from a GBS patient) is
genetically similar to the completely sequenced C. jejuni NCTC 11168 strain, whereas the expressions
of LOS genes were shown to strongly vary between respective strains. The presence of the identical
LOS locus in both C. jejuni ATCC 43446 and GB11 strains is probably the result of horizontal gene
transfer [72]. Additionally, the serum from the GB11 strain infected patient reacted only with the LOS
of GB11 and ATCC 43446 strains, but not with the LOS of the NCTC 11168 strain [72]. These findings
indicate that the horizontal exchange of genetic material between C. jejuni strains leads to variations in
LOS synthesis genes, which might be indeed related to C. jejuni-associated immunopathologies.
Interestingly, surface carbohydrate structures such as LOS play essential roles as permeability
barriers against hydrophobic antibiotics [83] and phenolic antimicrobials [84]. The inactivation of
the C. jejuni waaF gene (encoding a bacterial heptosyltransferase) results in the truncation of the
LOS inner core [85], causing a reduction in the minimal inhibitory concentrations (MICs) of phenolic
antimicrobials, such as butylated hydroxytoluene, p-coumaric acid, epigallocatechin gallate, and
hesperidin [84]. Furthermore, results from another study with mice that had been infected with C.
jejuni ∆lgtF, ∆waaF, and parental strains revealed that LOS may be involved in bacterial colonization
properties [24]. However, cultivation of the C. jejuni mutant strains showed that the growth of both
mutants was unaffected, indicating that the observed colonization defects of the ∆lgtF and ∆waaF
mutant strains might indeed constitute specific and interesting in vivo phenomena [24].
As mentioned above, LOS is essential for both cellular invasion and translocation of C. jejuni across
intestinal epithelial barriers [11,24,39–41,78]. The inactivation of sialyltransferase in GBS-associated C.
jejuni strains (expressing sialylated LOS) resulted in less distinct invasiveness into human epithelial
cells as compared to the respective wildtype bacteria [39]. In addition, C. jejuni isolates expressing
LOS mimicking ganglioside structure were shown to strongly attach to the Caco-2 intestinal epithelial
cells, as opposed to C. jejuni control isolates [78]. This is of clinical relevance given that C. jejuni
ganglioside-like LOS-expressing isolates are linked to severe enterocolitis with bloody diarrhea [78].
Finally, the variation of the LOS structure that may even mimic human ganglioside-like structures
by C. jejuni is a strategy to evade recognition by the host immune system. This mechanism is common
to bacterial pathogens in general.
6. Activation of TLR-4 Signaling by C. jejuni Lipooligosaccharide in Humans and Mice
Similar to LPS from different bacteria vertebrate species such as humans and mice recognize
C. jejuni LOS by specific binding of the lipid A moiety to the TLR-4 receptor complex of the innate
immune system (Figure 3). The TLR-4 signaling pathways have been extensively reviewed by
others [86–88]. Remarkably, mice have been shown to be approximately 10,000-fold more resistant
to LOS as compared to humans. Briefly, TLR-4 induces intracellular signaling through at least
two major pathways: (I) the Toll-Interleukin Receptor (TIR)-domain-containing interferon-β (TRIF),
TRIF-related adapter molecule (TRAM), TRIF–TRAM-pathway, which upregulates genes encoding
type I interferons (IFNs), and activates tumor necrosis factor (TNF)-α production and secretion; and
(II) the TIR-domain containing adapter protein (TIRAP), Myeloid differentiation primary response 88
(MyD88), TIRAP–MyD88-pathway, which regulates early nuclear factor kappa-light-chain-enhancer of
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activated B cells (NF-κB) activation and related inflammatory cytokine production such as interleukin
(IL)-12, responsible for the majority of the LPS/LOS responses [12,88–90] (Figure 3).
The immune responses induced by LPS or LOS variants of different Gram-negative bacteria upon
TLR-4 activation have been shown to differ remarkably [91]. While the LPS of the Helicobacter pylori
bacteria that are closely related to C. jejuni shows low reactivity with TLR-4 [92], the lipid A moiety of
C. jejuni LOS acts as a highly potent TLR-4 agonist [93]. Additionally, differences in the expression and
activation of TLR-4 by bacterial LPS or LOS were observed between vertebrate species (e.g., rabbits,
swains, dogs, humans, and mice). In mice, as in humans, cells of myeloid origin (such as monocytes,
macrophages and granulocytes) exhibit higher levels of TLR-4 expression than lymphoid cell types,
such as T and B cells [88]. However, murine plasmacytoid dendritic cells (pDCs) express TLR-4 in
contrast to human pDCs [94].
The main difference between murine and human TLR-4 activation is most probably due to the
LPS/LOS recognition pattern of the receptor complex [88]. Human, as opposed to murine, TLR-4 can
differentiate between the hexa- and penta-acylated forms of LPS produced by Pseudomonas aeruginosa,
for instance [95]. Furthermore, mice and humans differ regarding their TLR-4-expression levels upon
LPS challenge. While LPS increases the TLR-4 expression in human macrophages and monocytes [96],
murine peritoneal macrophages and neutrophils have shown decreased TLR-4 expression levels [97].
Additionally, the LPS/LOS doses being used in mice (1–25 mg/kg) are about 100-10,000 times higher
than the concentrations that are needed to induce severe disease including shock in humans [44]. These
observations underline the fact that the LPS/LOS tolerance of rodents, such as mice and rats, renders
those animals highly resistant to bacterial LPS and LOS [44,97].
Interestingly, there are several natural plant products such as curcumin derived from Curcuma
longa acting as highly effective TLR-4 antagonists by non-activate binding leading to competitive
inhibition of LPS/LOS functions [98]. Recently, it has been demonstrated that apoptosis induction,
tight junction redistribution, and increased inflammatory responses upon C. jejuni infection were
down-regulated after curcumin treatment in a co-culture model of human colon epithelial cells
HT-29/B6-GR/MR and immune THP-1 cells [99]. Additionally, curcumin could effectively ameliorate
the campylobacteriosis symptoms including apoptosis, T-cell mediated inflammatory responses and
colonic barrier dysfunction, observed in C. jejuni infected IL10−/− mice [99]. Furthermore, the increased
concentrations of pro-inflammatory cytokines such as TNF-α, IL.-1β and IL-6 in C. jejuni infected
co-cultures were down-regulated after curcumin treatment [99]. These results indicate that curcumin
in competition to TLR-4 binding antagonized local and systemic inflammatory responses triggered by
bacterial LPS/LOS [99,100]. Moreover, it has been reported that the competition between curcumin and
LPS/LOS to bind TLR-4 inhibited the MyD88-dependent pathway [101]. These results provide strong
evidence that the activation of TLR-4, and, thus, inflammatory diarrhea due to C. jejuni LOS induced
immune responses may be dampened by a curcumin enriched diet.
7. Generation of Secondary Abiotic Mice to Overcome Colonization Resistance
Several animal models, such as Galleria mellonella larvae [102], colostrum-deprived piglets [103],
gnotobiotic piglet [104], naïve swines [105], and ferrets [106] were successfully used for the study of
numerous aspects of C. jejuni pathogenesis. However, each animal model showed strong limitations
in terms of employing or comparing with human conditions upon C. jejuni infection [54]. The use of
mice as a model for C. jejuni infection was banned in the early 2000s, given that conventional wildtype
mice are highly resistant to C. jejuni colonization due to the physiological colonization resistance (CR)
exerted by the murine gut microbiota composition [43,46,50].
On the other hand, it has been known for decades that C. jejuni is able to colonize the intestines
of germfree BALB/c and C57BL/6 mice [56,59,60]. Table 1 (conventional and microbiota depleted
wild-type mice models) and 2 (genetically modified mice models) summarize various murine in vivo
studies, which are further described in detail in the text. In support, our studies revealed that C.
jejuni are able to colonize the gastrointestinal tract of secondary abiotic wildtype mice and secondary
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abiotic mice that had been associated with a complex human gut microbiota following FMT, resulting
in pro-inflammatory immune responses in the colon upon peroral infection [43,46,107]. Further
investigations demonstrated that murine CR against C. jejuni is abrogated by modifying the microbiota
composition towards increased intestinal commensal Escherichia coli loads, as seen following E. coli
feeding via the drinking water, during intestinal inflammation or in infant mice immediately after
weaning [58,108]. In the neonatal mouse model, C. jejuni was even able to colonize and cause clinical
signs such as severe diarrhea with increased mucus discharge, reduced weight gain, and sometimes
bloody stool, as early as 5 days post-infection [57], which is in line with a study by Lotz et al.,
demonstrating distinct differences between fetal, neonatal, and adult murine intestinal epithelial
cells, particularly regarding TLR-4 expressing features [109]. These findings revealed that CR and the
resilience to C. jejuni LOS are not developed in the early stage of murine life, as is discussed further
below (Chapter 9).
8. Rendering Mice Susceptible to LOS as Approach for Developing Valid C. jejuni
Infection Models
Stahl et al. developed an in vivo C. jejuni infection model through application of a single antibiotic
compound to mice [54]. Peroral application of vancomycin was accompanied by a depletion of
Bacteroidetes and Clostridia, and conversely, a promoted growth of Lactobacilli within the murine
intestinal lumen [54,110]. These alterations of the murine microbiota composition allowed C. jejuni
to colonize the intestinal lumen at high loads. Based on the finding that upon C. jejuni infection
vancomycin treated mice that were deficient in Single Ig IL-1-related receptor (SIGIRR) develop
intestinal inflammation, the authors proposed Sigirr−/− mice as a novel campylobacteriosis model.
Following peroral C. jejuni infection, Sigirr−/− mice exerted more severe gross pathology as compared
to wildtype mice, which was accompanied by higher expression levels of pro-inflammatory cytokines
such as TNF-α, IFN-γ, and IL-17 in the former versus the latter [54]. Furthermore, in this model, even
high load pathogenic colonization of the intestinal tract was accompanied by a relatively moderate
and self-limiting course of C. jejuni induced inflammatory disease [54,111]. In line with the high
LOS tolerance of mice discussed above, activation of murine as well as human SIGIRR inhibits the
MyD88-dependent signaling pathways [112] and, thus, the SIGIRR deficiency sensitizes mice to C.
jejuni LOS.
Similar to SIGIRR deficiency, the lack of the anti-inflammatory cytokine IL-10, which
inhibits TLR-dependent innate immune responses, abolished the murine resistance to LOS and
LPS [44,50,113–116]. It has recently been shown that C. jejuni colonize the intestinal tract of five to six
months old IL-10−/− mice with murine intestinal microbiota suffering from chronic colitis; however,
the clinical signs for severe human campylobacteriosis such as bloody diarrhea were missing [50,61].
Inspired by the initial use of IL10−/− mice as a clinical model for campylobacteriosis developed by
Mansfield et al. [56] and Lippert et al. [117], our group has generated a similar experimental model
for severe campylobacteriosis. For this purpose, IL10−/− mice were subjected to broad-spectrum
antibiotic treatment starting immediately after weaning in order to deplete the commensal gut
microbiota and, hence, to abrogate physiological CR preventing C. jejuni infection and furthermore,
in order to eliminate potential colitogenic stimuli from the commensal gut microbiota, leading to
chronic colitis in IL10−/− mice after 3 months or more [47,48,50]. Within one week following peroral
C. jejuni infection, these so-called secondary abiotic IL10−/− mice were stably colonized with high
pathogenic loads and suffered from non-self-limiting acute enterocolitis, characterized by wasting and
bloody inflammatory diarrhea, thus mimicking key features of severe human campylobacteriosis [50].
In addition, both C. jejuni-induced innate and adaptive pro-inflammatory immune responses were
not limited to the intestinal tract but could also be observed in extra-intestinal including systemic
compartments. The isolation of C. jejuni from mesenteric lymph nodes (MLNs), liver, kidneys,
spleen and cardiac blood indicated that invading bacteria had been able to translocate from the
inflamed intestines to extra-intestinal and even systemic compartments, further perpetuating the fatal
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inflammatory scenario. Overall, the secondary abiotic IL-10−/− mouse model has been proven valuable
to unravelling the immunopathological impact of distinct C. jejuni virulence factor involved in human
disease [28,43,47,48,52,64].
Remarkably, TLR-4 and IL10 double deficient (TLR-4−/− IL-10−/−) mice were far less compromised
and exhibited less distinct intestinal as well as extra-intestinal including systemic sequelae upon C.
jejuni infection. These results provide further evidence for a major role of TLR-4 mediated, LOS
dependent immunopathological mechanisms underlying campylobacteriosis [46,50]. In support, C.
jejuni infection experiments in TLR-4 deficient Sigirr−/− mice revealed similar results [54]. Following
peroral infection of TLR4−/− Sigirr−/− mice, C. jejuni colonized the intestines at high levels, but induced
rather mild, if any, signs of enteritis. Compared to Sigirr−/− counterparts, TLR-4 deficient Sigirr−/−
animals displayed less TNF-α and IFN-γ expression in ceca upon infection, which was comparable to
that assessed in uninfected control mice [54].
Recently, Giallourou et al. reported that zinc deficiency had a direct impact on symptom formation
in response to C. jejuni infection in antibiotic pretreated mice. In this mouse model, C. jejuni infection
induced both, intestinal and systemic inflammatory responses, underlining the relevance of this model
in clinical campylobacteriosis research [53]. In line with the fact that zinc deficiency increases the
sensitivity of mice to C. jejuni LOS, it is of note that significantly decreased serum zinc concentrations
were measured in patients with various bacterial infections [118,119], indicating a negative correlation
between zinc and susceptibility to infection-related disease (Figure 4). In support of this, challenging
rats with LPS of E. coli resulted in decreased serum zinc concentrations [120]. However, intraperitoneally
injected zinc protected mice against lethality that was induced by Salmonella typhimurium-derived LPS
injection [121]. Due to the anti-apoptotic [122] and anti-inflammatory properties of zinc [123–125],
its supplementation during pregnancy protected mice from E. coli-LPS induced preterm delivery
and fetal death by inhibiting LPS induced TNF-α release as well as NF-κB and mitogen-activated
protein kinase activation [126]. In support, polaprezine, a chelating compound of zinc and L-carnosine,
inhibited endotoxin shock in mice that had been challenged with LPS through inactivation of NF-κB
and, subsequently, reduced nitric oxide and TNF-α releases [127]. Additionally, zinc deficiency was
associated with increased LPS-induced TNF-α and IL-10 concentrations in mesenteric leukocytes
isolated from rats with dextran sulfate sodium induced colitis [128]. Notably, decreased plasma levels
of zinc could be measured in patients suffering from Crohn’s disease [129]. The molecular detection
of C. jejuni via real-time polymerase chain reaction in gastrointestinal biopsies revealed that patients
suffering from Crohn’s disease were more prone to C. jejuni infections as compared to individuals
without preexisting intestinal morbidities [130], which might be related to decreased zinc levels in
these patients [118]. Hence, zinc may be considered as a pharmacological agent particularly against
Gram-negative bacterial infection and to reduce infection burden via its immune-modulatory (i.e.,
anti-inflammatory) properties.
In summary, the abolishment of CR against C. jejuni in mice by depletion or modification of
the host specific gut microbiota in line with the sensitization of the animals to C. jejuni LOS by
genetic manipulation and zinc deficiency was crucial for the development of appropriately modified
murine infection models mimicking key features of campylobacteriosis and, thus, providing a better
understanding of cellular and molecular mechanisms underlying C. jejuni induced human disease
(Figure 4). Additionally, these results prove that TLR-4 dependent LOS signaling is essential for C.
jejuni-induced intestinal immunopathology in mice (Figure 3) and that innate immune responses
represent hallmarks in the immunopathogenesis of campylobacteriosis [46,50] (Figure 1). The extreme
resistance of birds to LPS/LOS might help to explain the lack of C. jejuni-mediated diseases in domestic
chickens, as is discussed in more detail below (Chapter 10).
9. The Use of Novel Murine Models of C. jejuni Infection in Actual Campylobacteriosis Research
Many recent studies investigated various immunopathological aspects of campylobacteriosis,
including C. jejuni-induced host responses and virulence factors in genetically modified mice with
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or without a specifically modified gut microbiota. As mentioned previously, it has been shown
that the murine microbiota is an essential physiological prerequisite for an effective CR directed
against C. jejuni. Besides secondary abiotic mice, mice harboring a human gut microbiota, infant
mice and mice displaying elevated commensal intestinal E. coli loads constitute valuable tools for
investigating C. jejuni-host interactions and infection-induced immunopathological responses of
varying severities [47,48,131].
Given the central role of IL-10 in maintaining gut homeostasis by the suppression of inflammatory
responses [132,133], it is also of great importance that conventional infant mice, which did not raise
a sufficient IL10 response in their intestines, become effectively colonized and infected by C. jejuni.
Most importantly, upon C. jejuni infection those infant mice display the typical course of self-limiting
campylobacteriosis seen in humans [56]. Moreover, infant mice cleared the intestinal infection and
developed granulomas at extra-intestinal sites including liver, kidneys and even the lungs. These
features highlight conventional infant mice as a useful model to study campylobacteriosis and possibly
the autoimmune responses leading to post-infectious sequelae.
In particular, the LOS sensitized secondary abiotic IL-10 deficient mice were successfully
used for groundbreaking studies for a better molecular understanding of immunopathogenesis
of campylobacteriosis. In this model, murine symptoms mimic human disease and induction of
intestinal inflammation strictly depends on the motility and invasive properties of C. jejuni [28]. It
is of note that commensal E. coli lacking any invasive or other pathogenic properties do not induce
pathology in this model [50]. This murine model was used recently for the successful treatment of C.
jejuni infection by the potent immune suppressor sirolimus (rapamycin), which inhibits intracellular
signaling by mammalian target of rapamycin (mTOR). The mTOR complexes 1 and mTORC2 play
important roles in regulating the activation of innate immune cell populations such as macrophages
and dendritic cells and induce cytokine production [134,135]. Therefore, mTOR signaling affects
several innate signaling pathways involved in TLR-4 activation and IL-10 production [135–137].
Additionally, mTOR-signaling is crucial for cell growth, proliferation, bacterial killing, and clearance of
infections [136]. In addition to mTOR, the phosphatidylinositol 3-kinase-γ (PI3K-γ, upstream of mTOR)
have been shown to modulate C. jejuni-induced colitis independently of T cell activation by recruitment
of neutrophilic granulocytes to the infected intestines and subsequent massive TNF secretion [62,138].
By using germ-free IL-10 and Rag2 double deficient mice the authors confirmed the hypothesis that
innate immune cells are the main cellular compartment responsible for campylobacteriosis. Most
importantly, inhibition of PI3K-γ signaling ameliorated C. jejuni-induced neutrophil accumulation
which correlated with reduced inflammatory responses. In fact, neutrophils have been shown to
exert potent pro-inflammatory responses upon LPS stimulation in vitro characterized by TLR-4
dependent TNF-α and IL-6 secretion [63,138]. To determine the role of mTOR in modulating TLR-4
activation, bone marrow-derived neutrophils were cultured with the mTOR inhibitor rapamycin [63].
Upon LPS stimulation, a reduction in TNF-α and IL-6 production by neutrophils could be observed,
further underlining the regulatory role of mTOR within the TLR-4 dependent LPS/LOS signaling
pathway [63]. Moreover, under the control of mTOR signaling, C. jejuni has been shown to produce
a cytolethal distending toxin, a genotoxin with DNase activity that is supposed to be involved in
the pathogenesis of colorectal cancer [139–141]. The inhibition of mTOR and, thus, the production
of genotoxin through rapamycin, could sufficiently dampen C. jejuni-induced carcinogenesis [139].
Hence, these results suggest that C. jejuni-induced colitis or colorectal tumorigenesis can be attenuated
by inactivation of mTOR signaling using pharmacological interventions such as rapamycin or PI3K-γ
inhibitors [62,139]. The mTOR signaling pathways represent a valuable novel target for therapeutically
interventions and drug development, enabling modulation of innate immune responses for treatment
of campylobacteriosis.
In the past few years, secondary abiotic as well as conventional NOD2 deficient
IL-10−/− (NOD2−/− IL-10−/−) mice were used to unravel the role of the innate immune
receptor nucleotide-oligonucleotide-domain 2 (NOD2) during campylobacteriosis and clearance
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of C. jejuni infection [51,142–146]. Following C. jejuni infection, secondary abiotic NOD2−/−
IL-10−/− mice harbored the pathogen at high loads, but developed less severe enterocolitis as
compared to IL-10−/− counterparts [51], indicating that NOD2 signaling increases the severity of
campylobacteriosis. Conflicting data from another study revealed that NOD2 signaling inhibits murine
campylobacteriosis [142]. These inconsistent results might be explained by differences in the genetic
background of mice as well as in the experimental set-ups between studies including the presence
or absence and distinct composition of the intestinal microbiota (e.g., antibiotic treatment duration,
different methods and the time point of sampling post-infection). The important role of the microbiota
composition in campylobacteriosis including the induction of neurological sequelae in frame of GBS
has recently been confirmed in elegant studies which paved the way for the use of murine models for
the study of immunopathology of Campylobacter induced GBS [147–149].
Even though the exact roles of NOD2 during campylobacteriosis remain unknown, several reports
have emphasized the complex modulatory crosstalk between NOD2 and TLR-4 signaling especially
in pro-inflammatory cytokine regulation [150–154], given that NOD2 is able to regulate the IL-12
production depending on TLR-4 intensity [155]. Furthermore, a clinical study revealed that a distinct
NOD2 gene mutation (homozygous for the 3020insC mutation) observed in Crohn’s disease patients
leads to massive TNF-α release by TLR-4 activation via LOS or LPS [156], indicating that a mutation in
the NOD2 gene is associated with increased LOS susceptibility. In line, NOD2 is able to inhibit TLR-2
and -4 mediated induction of pro-inflammatory cytokine secretion [157,158]. Taken together, these
results confirm the down-regulation of TLR-4 signaling by NOD2 activation not only in IBD [159],
but also in campylobacteriosis.
Most recently, the secondary abiotic IL10 deficient murine model of campylobacteriosis was
standardized and could be developed to the preclinical level for pharmaceutical analysis of alternative
drugs, including ascorbate and vitamin D, which effectively suppressed C. jejuni-induced inflammation
in the course of campylobacteriosis [20,160].
10. Differences in LOS Tolerance among Humans and Birds Impede the Development of
Prophylactic Measures against Campylobacteriosis
The major role of the endotoxin LOS in the inflammatory response to C. jejuni in both humans
and mice hampers the development of vaccines against C. jejuni. This is mainly due to the fact that it is
much more difficult to develop effective vaccines against endotoxin-driven morbidities as compared to
exotoxin-mediated diseases [74]. In addition, as mentioned previously, due to structural similarities
between C. jejuni-LOS and human gangliosides, antibodies directed against LOS might react with
human peripheral nerves [73,74]. Therefore, the association of anti-C. jejuni LOS antibodies with GBS
constitutes a substantial challenge if one might consider LOS a potential target molecule for vaccine
development. Likewise, the production of antibodies directed against C. jejuni flagella could be difficult
since the corresponding structural proteins are heavily glycosylated and show massive structural
variations among bacterial strains [161]. However, the capsular polysaccharide (CPS) might be regarded
as a promising candidate for conjugate vaccine development against C. jejuni. The advantage, as
opposed to LOS, is that neither mimicry between gangliosidic surface structures and C. jejuni CPS nor
association of CPS with GBS have been described to date [162]. Additionally, a mutated CPS (i.e., kpsS
mutant) has been shown to increase the susceptibility of C. jejuni to antibiotic and phenolic compounds
with antibacterial properties [84]. The kpsS gene encodes a β-linked 3-deoxy-d-manno-oct-2-ulosonic
acid (Kdo) transferase playing an important role in CPS synthesis [163]. Moreover, in the antibiotic
pretreated zinc deficient mouse model (described by Giallourou et al.), a C. jejuni kps mutant strain was
unable to colonize the murine intestines as opposed to the wildtype counterpart [53]. Additionally, a
monovalent capsule conjugate vaccine against C. jejuni has provided 100% protection against diarrheal
disease in monkeys [164]. However, since 47 different CPS serotypes have been identified for C. jejuni
so far [165], the development of capsule based vaccines needs further challenging investigations.
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Human Campylobacter infections result in severe inflammation of the intestinal mucosa, whereas
colonized avian species harbor C. jejuni as intestinal commensal bacteria and are usually lacking any
clinical signs [12]. In order to decrease the C. jejuni infection rates in humans, and in consequence,
the prevalence of severe human campylobacteriosis with the risk of subsequent post-infectious
sequelae, the vaccination of broiler chickens against C. jejuni is proposed to be one of the most efficient
strategies to reduce the intestinal C. jejuni loads in chickens and, thus, the risk of transfer to humans
via consumption of contaminated meat. The comparison of the C. jejuni colonization properties in
humans and chickens revealed host-specific differences in susceptibility to the bacteria. For example,
the characterization of chicken TLRs showed major species-specific characteristics [12]. C. jejuni
induces IFN-β, a key mediator of systemic inflammation, through TLR-4 activation in humans, but
not in chicken [12]. Furthermore, C. jejuni is highly susceptible to the chicken host defense peptide
cathelicidin-2 exerting antimicrobial activities [166]. These results may explain why Campylobacter is
able to colonize the avian gastrointestinal tract (with up to 109 CFU/g feces) without causing overt
clinical signs [166–168]. Since the C. jejuni-induced immune responses in humans and chicken are very
different, applying vaccines against C. jejuni to chickens could only reduce the Campylobacter transfer
to humans. However, there are several studies using clinical strains such as C. jejuni 81-176 in chicken
for vaccine development strategies [165,169].
Results from an in vivo study with Ross broiler chickens revealed four promising antigens
(YP437, YP562, YP9817 and YP9838) as potential vaccine candidates against the C. jejuni 81-176
strain [169]. The identified proteins were either flagella-associated proteins or hypothetical proteins.
The administration of these antigens could reduce cecal C. jejuni loads by up to 4.2 log orders of
magnitude in one trial. However, these promising results could not be reproduced, despite a strong
induced immune response upon application of the same antigen [169]. In addition, recent investigations
suggest C. jejuni N-glycan as a potential antigenic structure for vaccine development, since it constitutes
a surface carbohydrate with immunogenic properties in rabbits and humans [170,171]. In fact, a recent
study revealed the protective effect of N-glycan based vaccines against the C. jejuni 81-176 strain in SPF
Leghorn chickens [165].
Finally, it is noteworthy that chickens are more resistant to endotoxin derived from Gram-negative
bacteria, such as C. jejuni, as compared to mice and humans [166,172]. In contrast to humans, however,
C. jejuni mainly locate in the mucous layer of the crypts in chickens and do not directly adhere
to the avian intestinal epithelial cells [173–175]. Furthermore, C. jejuni rarely invade the intestinal
epithelium and if the internal organs are affected, no clinical signs of disease are observed in colonized
chickens [173,175,176]. Interestingly, the intravenous injection of high doses of purified E. coli-LPS (i.e.,
577 mg per kg body weight) into chickens induced only rather mild clinical signs such as diarrhea
and gasping, and the chickens recovered within two days post application. However, a LPS dose
of 45.5 mg per kg body weight was lethal to mice within four hours [172]. In humans, 4 ng per kg
body weight of Gram-negative bacterial endotoxin (e.g., C. jejuni-LOS) have been shown to activate
pro-inflammatory immune cytokine responses [177]. In a clinical study, the administration of 1 mg
Salmonella minnesota endotoxin to humans induced an inflammatory response with septic shock-like
symptoms that continued for several days [178].
These findings further underline that differences in LOS susceptibility and resistance between
vertebrate species such as humans on one hand and chicken and mice on the other might provide
explanations for the completely divergent species-specific reactions to C. jejuni.
11. Conclusions
The major role of innate immunity and C. jejuni LOS as a main pathogenicity factor in human
campylobacteriosis and the extreme LOS resistance of mice and birds has provided a substantial key to
the understanding of symptomless C. jejuni colonization in chickens on one hand, versus severe infection
in humans on the other. In line with a better appreciation of the CR created by the individual microbiota
of vertebrates, these historically neglected but valid insights enabled the development of several
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novel murine models for campylobacteriosis research—all based on the reduction in species-specific
resistance to both, bacterial colonization and LOS resistance. The resulting LOS sensitized murine C.
jejuni infection models lacking CR mimic key features of human campylobacteriosis and will help to
unravel the molecular mechanisms underlying the immunopathology of intestinal infection as well as
post-infectious sequelae. Their standardization and use for preclinical pharmaceutical evaluation have
paved the way for the identification of novel therapeutic and prophylactic options in order to combat
campylobacteriosis, including collateral damages, in the future.
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IBD inflammatory bowel disease




Kdo β-linked 3-deoxy-d-manno-oct-2-ulosonic acid
LOS lipooligosaccharide
LPS lipopolysaccharide
MCP-1 monocyte chemoattractant protein 1
MFS Miller-Fisher syndrome
MIC minimum inhibitory concentration
MLN mesenteric lymph nodes
mRNA messenger ribonucleic acid
mTOR mammalian target of rapamycin
mTORC mTOR complex
mg milligram
MAPK mitogen-activated protein kinase
MyD88 Myeloid differentiation primary response 88
ng nanogram
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NOD2 nucleotide-oligonucleotide-domain 2
pDCs plasmacytoid dendritic cells
PI3K-γ phosphatidylinositol 3-kinase-γ
SIGIRR Single Ig IL-1-related receptor
SPF Specific pathogen-free
T6SS type VI secretion system
TIR toll-Interleukin receptor domain
TLR Toll-like receptor
TNF tumor necrosis factor
TRAM TRIF-related adapter molecule
TRIF TIR-domain-containing adapter inducing interferon-β
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